Last reviewed · How we verify
GSK Biologicals' AS01B adjuvant
Stimulates Toll-like receptor 4 and MyD88-dependent signaling pathway
Stimulates Toll-like receptor 4 and MyD88-dependent signaling pathway Used for Hepatitis B, Hepatitis E.
At a glance
| Generic name | GSK Biologicals' AS01B adjuvant |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Adjuvant |
| Target | Toll-like receptor 4 |
| Modality | Biologic |
| Therapeutic area | Vaccines |
| Phase | Phase 2 |
Mechanism of action
AS01B adjuvant is a combination of the saponin QS-21 and the liposome-based 3-O-desacyl-4'-monophosphoryl lipid A (MPLA).
Approved indications
- Hepatitis B
- Hepatitis E
Common side effects
- Pain
- Redness
- Swelling
Key clinical trials
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases (PHASE4)
- Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali (PHASE1)
- Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali (PHASE2)
- Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B (PHASE1)
- Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults (PHASE2)
- Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults (PHASE1, PHASE2)
- Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects (PHASE2)
- Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals' AS01B adjuvant CI brief — competitive landscape report
- GSK Biologicals' AS01B adjuvant updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI